fig1

Figure 1. The current therapeutic landscape of malignant pleural mesothelioma (MPM). A list of the first and second/third-line therapies in relation to their median overall survival (mOS). *FDA/EMA/NICE approval (for Nivolumab-Ipilimumab, FDA approval was granted in 2020, and EMA/NICE approval in 2021). Vin: Vinorelbine; Gem: gemcitabine.